- Email: [email protected]
Antiviral method and antiviral agent (M Mori et al, JP)
. . . cultures in the diagnosis of osteoporosis and for testing potential osteoporosis therapeutic agent (0 Josimovic-Alasevic et al, DE)
Codon GmbH Gesellschaft fur Molekulare Medizin und Biotechnologie and the inventors NOW0 96140873,PCT . .. The invention also concerns the use of these cell cultures in diagnosing osteoporosis... > Detection of Cryptosporidium parvum (Ml Steele et a/, US)
The Board of Regents of the University of Oklahoma N” WO 96140926. PCT. A method and kit for the detection of Cryptosporidiz4m pnrvum in aquatic and biological samples such as surface water of feces... > Methods, kits and compositions for diagnosing papillomavirus infection (PM Howley et a/, US)
> Haemophilus pilus vaccines ton, US)
influenzae (CC Brin-
Bactex Inc and the inventor N” WO 96138476, PCT. . . There is further provided a purified multivalent intact pilus vaccine composition for protecting subjects against infections caused by piliated H influenzae which comprises a pharmaceutically acceptable carrier and whole H inf7twmze pili, designated vaccine pili... > A replication-defective adenovirus human type 5 recombinant as a vaccine carrier (HC Ertl and JM Wilson, US)
The Wistar Institute of Anatomy and Biology, the Trustees of the University of Pennsylvania and the inventors N” WO 96139178, PCT. . . . which contains a complete deletion of its El gene and at least a partial deletion of its E3 gene...
President and Fellows of Harvard College NOW0 96141018. PCT.
> Infectious rus PKD-53 lent vaccine pravati et a/,
z Relaxin diagnostic assays and kits, and methods and uses thereof (C Schwabe et a/, US)
The Government of the United States of America, the Department of Health and Human Services and the Mahidol University at Salaya N” WO 96140933. PCT. The invention relates to infectious cDNA clones for Dengue 2 virus, strain 16681, and its live, attenuated vaccine derivative, PDK-53 (DEN-2 PDK-53). The invention also relates to infectious cDNA clones for chimeric viruses characterized as expressing structural genes of a Dengue 1, Dengue 3, or Dengue 4 attenuated virus in the context of nonstructural genes of the Dengue 2 PDK-53 virus...
Connective Therapeutics Inc, and Medical University of South Carolina NOW0 96141167, PCT. . The present invention further relates to methods for determination of relaxin levels in body fluids for the diagnosis of various malignancies. Further, the present invention further relates to diagnostic assays and kits...
> Virus combine al, FR)
myxomateux (S Bertagnoli
reet
lnserm et Bcole nationale veterinaire de Toulouse N” 2736358, FR. Un virus myxomateux recombinant vivant attenui, comprenant au moins une sequence nucleotidique codant et exprimant, un polypeptide antigenique, sous la dependance d’un promoteur ins&i dans I’un des genes non essentiels pour la replication dudit virus... 46 BIOFUTLlR165
l
Mars1997
Dengue 2 vias quadrava(N BhamaraUS, TH)
> Nucleic acid respiratory syncytial virus vaccines Li et a/, CA)
> Suppressor of HIV replication and transcription (DP Bolognesi et a/, US)
Duke University Medical Center N” WO 96/39172, PCT. . . The invention relates to isolation of clonal CD8+ cells lines that produce the entiviral activity and the development of an assay system for detection of the antiviral activity. The clonal cell lines and the assay system, described herein. may be utilized to purify characterize and clone the CDS+ suppressor molecule... > Nucleotide and amino acid sequences of hypervariable region 1 of the enveloppe 2 gene of hepatitis C virus (J Bukh et a/ US)
The Government of the United States of America, the Department of Health and Human Services N” WO 96/40764, PCT. > Antiviral method and antiviral agent (M Mori et a/,
JW
Otsuka Pharmaceutical Co Ltd N”W0 96/41643, PCT. . . This drug comprises interferon together with at least one component selected from the group consisting of zinc salts and zinc complexes.
> Means for detecting and preventing HIV infection involving use of receptors or binding sites capable of interacting with gp120 (F Veas and F Jansen, FR)
Orstom et les inventeurs N” WO 96141884, PCT. The new gp120 receptors or binding sites of the invention are found on CD4+ cells, but differ from the CD4 binding receptor which is blocked when reacting CD4+ cell with a monoclonal antibody directed against the gp120 binding site of CD4...
(X
Connaught Laboratories Ltd and the inventors N” WO 96140945, PCT. Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence...
> Treatment sis of prostate Bander, US)
and
diagnocancer (N
Cornell Research Foundation Inc N” WO 96/39185, PCT. The present invention is directed to the use of antibo-
dies or binding portions thereof or probes which recognize an antigen of normal, benign, hyperplasic, and cancerous prostate epithelial cells of portions thereof. These antibodies or binding portions thereof or probes can be labeled and used for detection of such cells... > Monoclonal antibody fragment to human ovarian cancers (KO Lloyd et a/, US, TR)
Sloan-Kettering Institute for Cancer Research and the inventors N” WO 96140295. PCT. > Colorectal cancer risk factor detection and treatment (AM Buchberg et a/, u-9
Thomas Jefferson University and the inventors N” WO 96141003. PCT.
i > lmmunoregulatory tein LST-1 (E Weiss,
proDE)
Boehringer Mannheim GmbH N” 750039, EP. The invention concerns a new immunoregulatory protein LST-1, nucleic acid sequences coding for this protein, a process for the isolation of this protein, as well as its use for the production of a therapeutic agent... > Modified cells and methods for inhibiting xenograft rejection (C Donnelly et a/, US)
Diacrin Inc N” WO 96138543, PCT. ... The methods involve altering at least one antigen on the surface of a donor cell prior to transplantation to reduce the immunogenicity of the cell in a recipient subject. Preferably, an MHC class I antigen... > aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibodymediated pathologies (EJ Victoria et a/, US)
La Jolla Pharmaceutical Co N” WO 96/40197, PCT. ... Optimized analogs lacking T cell epitopejs) are useful as conjugates for treating aPL antibody-mediated diseases...
Codon GmbH Gesellschaft fur Molekulare Medizin und Biotechnologie and the inventors NOW0 96140873,PCT . .. The invention also concerns the use of these cell cultures in diagnosing osteoporosis... > Detection of Cryptosporidium parvum (Ml Steele et a/, US)
The Board of Regents of the University of Oklahoma N” WO 96140926. PCT. A method and kit for the detection of Cryptosporidiz4m pnrvum in aquatic and biological samples such as surface water of feces... > Methods, kits and compositions for diagnosing papillomavirus infection (PM Howley et a/, US)
> Haemophilus pilus vaccines ton, US)
influenzae (CC Brin-
Bactex Inc and the inventor N” WO 96138476, PCT. . . There is further provided a purified multivalent intact pilus vaccine composition for protecting subjects against infections caused by piliated H influenzae which comprises a pharmaceutically acceptable carrier and whole H inf7twmze pili, designated vaccine pili... > A replication-defective adenovirus human type 5 recombinant as a vaccine carrier (HC Ertl and JM Wilson, US)
The Wistar Institute of Anatomy and Biology, the Trustees of the University of Pennsylvania and the inventors N” WO 96139178, PCT. . . . which contains a complete deletion of its El gene and at least a partial deletion of its E3 gene...
President and Fellows of Harvard College NOW0 96141018. PCT.
> Infectious rus PKD-53 lent vaccine pravati et a/,
z Relaxin diagnostic assays and kits, and methods and uses thereof (C Schwabe et a/, US)
The Government of the United States of America, the Department of Health and Human Services and the Mahidol University at Salaya N” WO 96140933. PCT. The invention relates to infectious cDNA clones for Dengue 2 virus, strain 16681, and its live, attenuated vaccine derivative, PDK-53 (DEN-2 PDK-53). The invention also relates to infectious cDNA clones for chimeric viruses characterized as expressing structural genes of a Dengue 1, Dengue 3, or Dengue 4 attenuated virus in the context of nonstructural genes of the Dengue 2 PDK-53 virus...
Connective Therapeutics Inc, and Medical University of South Carolina NOW0 96141167, PCT. . The present invention further relates to methods for determination of relaxin levels in body fluids for the diagnosis of various malignancies. Further, the present invention further relates to diagnostic assays and kits...
> Virus combine al, FR)
myxomateux (S Bertagnoli
reet
lnserm et Bcole nationale veterinaire de Toulouse N” 2736358, FR. Un virus myxomateux recombinant vivant attenui, comprenant au moins une sequence nucleotidique codant et exprimant, un polypeptide antigenique, sous la dependance d’un promoteur ins&i dans I’un des genes non essentiels pour la replication dudit virus... 46 BIOFUTLlR165
l
Mars1997
Dengue 2 vias quadrava(N BhamaraUS, TH)
> Nucleic acid respiratory syncytial virus vaccines Li et a/, CA)
> Suppressor of HIV replication and transcription (DP Bolognesi et a/, US)
Duke University Medical Center N” WO 96/39172, PCT. . . The invention relates to isolation of clonal CD8+ cells lines that produce the entiviral activity and the development of an assay system for detection of the antiviral activity. The clonal cell lines and the assay system, described herein. may be utilized to purify characterize and clone the CDS+ suppressor molecule... > Nucleotide and amino acid sequences of hypervariable region 1 of the enveloppe 2 gene of hepatitis C virus (J Bukh et a/ US)
The Government of the United States of America, the Department of Health and Human Services N” WO 96/40764, PCT. > Antiviral method and antiviral agent (M Mori et a/,
JW
Otsuka Pharmaceutical Co Ltd N”W0 96/41643, PCT. . . This drug comprises interferon together with at least one component selected from the group consisting of zinc salts and zinc complexes.
> Means for detecting and preventing HIV infection involving use of receptors or binding sites capable of interacting with gp120 (F Veas and F Jansen, FR)
Orstom et les inventeurs N” WO 96141884, PCT. The new gp120 receptors or binding sites of the invention are found on CD4+ cells, but differ from the CD4 binding receptor which is blocked when reacting CD4+ cell with a monoclonal antibody directed against the gp120 binding site of CD4...
(X
Connaught Laboratories Ltd and the inventors N” WO 96140945, PCT. Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence...
> Treatment sis of prostate Bander, US)
and
diagnocancer (N
Cornell Research Foundation Inc N” WO 96/39185, PCT. The present invention is directed to the use of antibo-
dies or binding portions thereof or probes which recognize an antigen of normal, benign, hyperplasic, and cancerous prostate epithelial cells of portions thereof. These antibodies or binding portions thereof or probes can be labeled and used for detection of such cells... > Monoclonal antibody fragment to human ovarian cancers (KO Lloyd et a/, US, TR)
Sloan-Kettering Institute for Cancer Research and the inventors N” WO 96140295. PCT. > Colorectal cancer risk factor detection and treatment (AM Buchberg et a/, u-9
Thomas Jefferson University and the inventors N” WO 96141003. PCT.
i > lmmunoregulatory tein LST-1 (E Weiss,
proDE)
Boehringer Mannheim GmbH N” 750039, EP. The invention concerns a new immunoregulatory protein LST-1, nucleic acid sequences coding for this protein, a process for the isolation of this protein, as well as its use for the production of a therapeutic agent... > Modified cells and methods for inhibiting xenograft rejection (C Donnelly et a/, US)
Diacrin Inc N” WO 96138543, PCT. ... The methods involve altering at least one antigen on the surface of a donor cell prior to transplantation to reduce the immunogenicity of the cell in a recipient subject. Preferably, an MHC class I antigen... > aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibodymediated pathologies (EJ Victoria et a/, US)
La Jolla Pharmaceutical Co N” WO 96/40197, PCT. ... Optimized analogs lacking T cell epitopejs) are useful as conjugates for treating aPL antibody-mediated diseases...